Post-marketing surveillance of encorafenib in combination with binimetinib in Japanese patients with BRAF-mutant melanoma
The safety and effectiveness of encorafenib plus binimetinib in Japanese patients with BRAF-mutant malignant melanoma were similar to data reported in COLUMBUS; no new safety concerns were identified.
Authors
- Naoya Yamazaki (ORCID: https://orcid.org/0000-0002-9638-0428)
- Hidenori Sakata
- Hisashi Uhara (ORCID: https://orcid.org/0000-0001-5391-3397)
- Osamu Iida
- Teruaki Katayama (ORCID: https://orcid.org/0009-0003-9644-9397)
Institutions
- Sapporo Medical University (JP)
- Ono Pharmaceutical (Japan) (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s10147-025-02693-6
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ono Pharmaceutical